Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label multiple-dose APL-2 study in PNH
2017-005140-16Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Mar 2018
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2017-005140-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005140-16.